Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone250-708-4272
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$460,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Tuesday, March, 19th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.03. The biotechnology company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 48.36% and a negative net margin of 8,435.08%. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What price target have analysts set for AUPH?
4 brokers have issued 12 month target prices for Aurinia Pharmaceuticals' stock. Their predictions range from $11.00 to $24.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 129.7% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.
What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $88M, which includes a DCF analysis based asset value for AG013, with a 18% discount rate and 2% terminal growth rate, excluding debt and assuming 46M shares outstanding at the end of 1Q20." (5/15/2019)
- 2. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (3/20/2019)
- 3. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating and increasing our PT to $24 from $18 on Aurinia following 4Q18/2018 fiscal earnings. We are increasing our price target due to Aurinia’s recent Notice of Allowance regarding a U.S. patent related to voclosporin’s method of use. We no longer anticipate a decrease in the voclosporin price in 2027 from generic entry. The largest driver of Aurinia’s shares will likely be a focus on Phase 3 data for voclosporin for the treatment of lupus nephritis (LN), which could be announced by year-end 2019. Aurinia is creating a blueprint for how to advance the remaining pipeline, which targets additional significant market opportunities." (3/19/2019)
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
News articles about AUPH stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Myokardia (MYOK), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Uniqure (QURE), Insmed (INSM), Ligand Pharmaceuticals (LGND), Portola Pharmaceuticals (PTLA), Endocyte (ECYT), Xencor (XNCR), AnaptysBio (ANAB), Allakos (ALLK), Akcea Therapeutics (AKCA), Arrowhead Pharmaceuticals (ARWR), Pacira Biosciences (PCRX) and Nabriva Therapeutics (NBRV).
What other stocks do shareholders of Aurinia Pharmaceuticals own?
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
Who are Aurinia Pharmaceuticals' major shareholders?
Aurinia Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (5.64%), FMR LLC (4.97%), Goldman Sachs Group Inc. (1.50%), BlackRock Inc. (0.97%), Redmile Group LLC (0.35%) and Creative Planning (0.23%).
Which major investors are selling Aurinia Pharmaceuticals stock?
AUPH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., BlackRock Inc., Morgan Stanley, Ironwood Investment Management LLC and Patriot Financial Group Insurance Agency LLC.
Which major investors are buying Aurinia Pharmaceuticals stock?
AUPH stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Redmile Group LLC, Renaissance Technologies LLC, Wells Fargo & Company MN, Knott David M, Creative Planning, Dynamic Technology Lab Private Ltd and Spark Investment Management LLC.
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUPH stock can currently be purchased for approximately $6.64.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of $608.56 million and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]
MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
